| AEterna Zentaris is a biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Co.'s lead product, Macrilen (macimorelin) is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency. Macrilen is marketed in the United States through a license and assignment agreement with Novo Nordisk A/S. Co. is also pursuing the development of macimorelin for the diagnosis of child-onset growth hormone deficiency. Co.'s principal focus is on the commercialization of Macrilen and it does not have any other approved products. We show 4 historical shares outstanding datapoints in our coverage of AEZS's shares outstanding history.|
Understanding the changing numbers of AEZS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AEZS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AEZS by allowing them to research AEZS shares outstanding history
as well as any other stock in our coverage universe.